Drug reference
empagliflozin-linagliptin-metformin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Gastrointestinal Tract (Combination(GIT))
Mechanism of action
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
Linagliptin: DPP-4 inhibitor; increases and prolongs incretin hormone activity, which is inactivated by DPP-4 enzyme; incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells
Common side effects
- Constipation
- Hypoglycaemia
- Upper respiratory infections
- Urinary tract infections
- Nasopharingitis
- Gastroenteritis
- Diarrhea
Boxed warnings
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain) Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL Risk factors include…
Contraindications
- Hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients in the product
- Metabolic acidosis, including diabetic ketoacidosis
- Severe renal impairment (eGFR <30 mL/min/1.73 m2), ESRD, or dialysis
Related conditions
Frequently asked questions
What drug class is empagliflozin-linagliptin-metformin?
empagliflozin-linagliptin-metformin belongs to: Gastrointestinal Tract.
How does empagliflozin-linagliptin-metformin work?
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion Linagliptin: DPP-4 inhibitor; increases and prolongs incretin hormone activity, which is inactivated by DPP-4 enzyme; incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells
What are the common side effects of empagliflozin-linagliptin-metformin?
Constipation, Hypoglycaemia, Upper respiratory infections, Urinary tract infections, Nasopharingitis, Gastroenteritis, Diarrhea
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.